How Ph.D. was paid
$1.4M in total for 2024, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Stock | Options | Other | Total |
|---|---|---|---|---|---|---|
| Hans T. Schambye, M.D., Ph.D.President and Chief Executive Officer | $526,084 | $303,156 | $142,000 | $258,879 | $199,431 | $1,429,550 |
| Lori FirmaniChief Financial Officer | $261,188 | $90,000 | $39,050 | $76,314 | $95,340 | $561,892 |
| Jonathan FreveFormer Chief Financial Officer | $328,182 | — | $420,572 | $71,000 | — | $819,754 |
| Garrett WinslowGeneral Counsel | $400,400 | $192,192 | $71,000 | $91,576 | $142,200 | $897,368 |
What changed and why
- 1,429,550 dollars was awarded to CEO Hans T. Schambye for fiscal year 2024.
- 965,115 dollars was total compensation for the CEO in the prior year 2023.
- 400,000 dollars severance payment was made to former CFO Jonathan Freve in August 2024.
- 68,640 dollars retention bonus was paid to CFO Lori Firmani following the Bridge Medicines purchase.
Other Damora Therapeutics proxy statements
- 2026 proxy statement
Hans T. Schambye, M.D., Ph.D. paid $1.3M (-9% on the year).
Filed Apr 29, 2026
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.